Hyo-eun Carrie Bhang

Hyo-eun Carrie Bhang has a diverse and extensive work experience in the field of scientific research and drug discovery.

Hyo-eun Carrie is currently employed at Treeline Biosciences as the Director of Drug Discovery Biology, a position they assumed in June 2021.

Prior to that, Bhang served as the Associate Director of Biology at Civetta Therapeutics from September 2019 to June 2021.

Hyo-eun Carrie had a long tenure at Novartis Institutes for BioMedical Research (NIBR), where they held various roles. Bhang was an Investigator III in Oncology Pharmacology from October 2017 to September 2019, an Investigator II in Oncology Pharmacology from December 2014 to October 2017, and a Presidential Postdoctoral Fellow in Oncology from January 2012 to December 2014.

Early in their career, they worked as a Postdoctoral Research Fellow in Radiology at Johns Hopkins Medicine from November 2010 to January 2012. Prior to that, they were a Ph.D. Candidate in Pharmacology at Johns Hopkins Medicine from August 2004 to October 2010. During their doctoral studies, Bhang focused on developing in vivo theranostic agents for cancer metastasis detection using the PEG-3 promoter, which exhibits general cancer cell specificity.

Hyo-eun Carrie Bhang has a Ph.D. in Pharmacology/Molecular Imaging from The Johns Hopkins University School of Medicine. Hyo-eun Carrie also participated in the Education Abroad Reciprocal Exchange Program in Biological Sciences at UC San Diego. Prior to that, they earned a B.S. in Biotechnology from Yonsei University.